Update date
30 Apr 2022
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest reported research and development expense: $2,543,481. Open the source-backed page to compare this metric with the newest filing-backed context.
Update date
30 Apr 2022
Page type
Metric history
Latest period
Q1 2022
SEC-backed company facts were refreshed from filings filed on 28 Oct 2026.
Benchmark Context
BriaCell Therapeutics Corp. is outside the visible top 120 companies for research and development expense in the current sample.
Compared with
Compared with 120 companies reporting research and development expense in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.1x the current sample midpoint. Research And Development Expense is up about 126% versus the comparable prior period.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Financial Metric Page
Latest period: Q1 2022. Period end: 30 Apr 2022. Units: USD. Frequency: quarterly and annual.
Research And Development Expense is reported in company XBRL facts filed with the SEC.
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | ASTRAZENECA PLC (azn) | $14,232,000,000 | Year - 31 Dec 2025 | Open ASTRAZENECA PLC Research And Development Expense |
| 2 | NOVARTIS AG (nvs) | $11,200,000,000 | Year - 31 Dec 2025 | Open NOVARTIS AG Research And Development Expense |
| 3 | TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (tsm) | $6,227,000,000 | Year - 31 Dec 2024 | Open TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD Research And Development Expense |
| 4 | GENMAB A/S (gmab) | $1,606,000,000 | Year - 31 Dec 2025 | Open GENMAB A/S Research And Development Expense |
| 5 | ARGENX SE (argx) | $1,364,132,000 | Year - 31 Dec 2025 | Open ARGENX SE Research And Development Expense |
| 6 | Shell plc (shel) | $1,170,000,000 | Year - 31 Dec 2025 | Open Shell plc Research And Development Expense |
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2022 | $2,543,481 | +$1,418,056 | +126% | 01 Feb 2022 | 30 Apr 2022 | 6-K | 13 Jun 2022 | 2022 | Q3 | |
| Q4 2021 | $1,733,555 | +$1,567,963 | +947% | 01 Nov 2021 | 31 Jan 2022 | 6-K | 15 Mar 2022 | 2022 | Q2 | |
| Q1 2021 | $1,125,425 | 01 Feb 2021 | 30 Apr 2021 | 6-K | 13 Jun 2022 | 2022 | Q3 | |||
| Q4 2020 | $165,592 | 01 Nov 2020 | 31 Jan 2021 | 6-K | 15 Mar 2022 | 2022 | Q2 | |||
| Q2 2019 | $4,002,676 | 30 Jul 2019 | 01 Aug 2019 | 40-F/A | 16 Nov 2021 | 2021 | FY |
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2021 | $1,315,496 | -$1,110,342 | -46% | 01 Aug 2020 | 31 Jul 2021 | 40-F/A | 16 Nov 2021 | 2021 | FY |
| 2020 | $2,425,838 | 02 Aug 2019 | 31 Jul 2020 | 40-F/A | 16 Nov 2021 | 2021 | FY |